Trial Profile
A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-4
- Sponsors AbbVie
- 28 Mar 2019 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir treatment for 8-16 weeks from 9 Phase II and Phase III trials (NCT02243280, NCT02243293, NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, and NCT02446717) published in the Clinical Infectious Diseases.
- 13 Nov 2018 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir in patients with HCV genotype GT 1-6 infection and severe renal impairment using data from EXPEDITION-4 and EXPEDITION-5 studies (n=205), presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 30 Jul 2018 Results of pooled data from 8 studies (SURVEYOR-1, 2, ENDURANCE-1, 2, 3, 4, and EXPEDITION-1, 4), were published in the Antimicrobial Agents and Chemotherapy.